“The Global Pharma Contract Sales market is estimated to reach $11bn in 2025” says Visiongain report

27 February 2020
Pharma

Dominated by the contract sales detailing services, the Global Pharma Contract Sales Market is estimated to grow at a CAGR of 6.3%% from 2020 to 2030.

Outsourcing is a growing trend in the pharma industry, with contract providers now offering services from the drug discovery stage through to commercialisation, manufacturing and sales.

Both large and small pharma companies are becoming increasingly reliant upon contract service providers, as they look to focus on perceived core competencies in-house, although companies can now outsource almost any task. Significant changes have been made to pharma sales strategies, with many leading companies cutting sales forces. As pharmaceutical companies are restructuring and cutting operational cost, jobs are being cut especially in divisions that can be outsourced.

Leading companies such as CMIC, IQVIA, Marvecs, Oncall, UDG Healthcare and others are investing in the pharma contract sales market.

The lead analyst commented that "Visiongain believes that, in this 10-year forecast period, the largest CSOs will be the greatest beneficiaries of strategic partnerships with the pharma industry. These companies will gradually enter into more complex agreements with their pharma partners, including risk-sharing and licensing agreements."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever